Literature DB >> 17190770

Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models.

Daniel Neureiter1, Steffen Zopf, Thorsten Leu, Otto Dietze, Cornelia Hauser-Kronberger, Eckhart G Hahn, Christoph Herold, Matthias Ocker.   

Abstract

OBJECTIVE: Pancreatic cancer continues to be an urgent clinical problem. We used the novel DNA methyltransferase inhibitor Zebularine and the histone deacetylase inhibitor SAHA to investigate the epigenetic influence on viability and differentiation of the pancreatic cancer cell lines YAP C, DAN G and Panc-89 in vitro and in vivo.
MATERIAL AND METHODS: Cell vitality, proliferation and expression of PDX-1, cytokeratin 7 and 20, chromogranin A, vimentin, bax and bcl-2 were determined on the protein and mRNA level in vitro and in a subcutaneous xenograft model.
RESULTS: A time- and dose-dependent increase of apoptosis, paralleled by decreased proliferation, was observed after incubation with single agents or a combination therapy with lower concentrations. This was associated with up-regulation of pro-apoptotic bax and a phenotypic stabilization by the enhanced expression of cytokeratin 7. In vivo, growth of xenografts was delayed with the most pronounced effect in Panc-89 after 1 week of daily intraperitoneal injections of Zebularine paralleled with CK7 up-regulation and down-regulation of dedifferentiation markers.
CONCLUSIONS: Epigenetic modulation via inhibition of DNA methyltransferase and histone deacetylase induces apoptosis in human pancreatic cancer cells in vitro and delays xenograft growth in vivo, which is associated with a morphological/molecular phenotypic stabilization. These compounds may therefore be suitable as adjunctive therapeutic agents in the treatment of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17190770     DOI: 10.1080/00365520600874198

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  32 in total

Review 1.  Current evidence for histone deacetylase inhibitors in pancreatic cancer.

Authors:  Ioannis Koutsounas; Constantinos Giaginis; Efstratios Patsouris; Stamatios Theocharis
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

2.  DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.

Authors:  Min Chen; Daniel Shabashvili; Akbar Nawab; Sherry X Yang; Lisa M Dyer; Kevin D Brown; Melinda Hollingshead; Kent W Hunter; Frederic J Kaye; Steven N Hochwald; Victor E Marquez; Patricia Steeg; Maria Zajac-Kaye
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

Review 3.  Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy.

Authors:  Eckhard Klieser; Stefan Swierczynski; Christian Mayr; Johanna Schmidt; Daniel Neureiter; Tobias Kiesslich; Romana Illig
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

4.  An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer.

Authors:  Jesper B Andersen; Valentina M Factor; Jens U Marquardt; Chiara Raggi; Yun-Han Lee; Daekwan Seo; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  Sci Transl Med       Date:  2010-10-20       Impact factor: 17.956

5.  The pan-deacetylase inhibitor panobinostat modulates the expression of epithelial-mesenchymal transition markers in hepatocellular carcinoma models.

Authors:  Pietro DI Fazio; Roberta Montalbano; Karl Quint; Beate Alinger; Ralf Kemmerling; Tobias Kiesslich; Matthias Ocker; Daniel Neureiter
Journal:  Oncol Lett       Date:  2012-10-01       Impact factor: 2.967

6.  Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.

Authors:  Taofeek K Owonikoko; Suresh S Ramalingam; Beatriz Kanterewicz; Trent E Balius; Chandra P Belani; Pamela A Hershberger
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

7.  Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.

Authors:  Madhavi Billam; Michele D Sobolewski; Nancy E Davidson
Journal:  Breast Cancer Res Treat       Date:  2009-05-21       Impact factor: 4.872

8.  DLC1: a significant GAP in the cancer genome.

Authors:  Aurelia Lahoz; Alan Hall
Journal:  Genes Dev       Date:  2008-07-01       Impact factor: 11.361

9.  Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.

Authors:  Martin Haefner; Thilo Bluethner; Manuel Niederhagen; Christian Moebius; Christian Wittekind; Joachim Mossner; Karel Caca; Marcus Wiedmann
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

Review 10.  Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects.

Authors:  Daniel Neureiter; Tarkan Jäger; Matthias Ocker; Tobias Kiesslich
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.